Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

Sponsor
GlaxoSmithKline
Study ID
NCT04971590
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Participant completed survey — OTHER
    Participants will be required to complete the participant survey.
  • Medical chart review — OTHER
    Data will be collected from medical charts of participants.

Study Details

This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).

Key Dates

Start date
Sep 14, 2021
Status verified
Jan 2026
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024

Study Design

Enrollment
193 participants (actual)

Arms

  • Arm: Participants with Lupus Nephritis

Primary Outcome Measure

Number of Participants Categorized by Demographic Characteristics [ Time Frame: At Baseline (Day 1) ]

Related Studies